At a glance
- Originator Freie Universitat Berlin
- Developer Yamasa Corporation
- Class Antihistamines; Neuroprotectants; Nootropics; Small molecules
- Mechanism of Action Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cognition disorders